MA33418B1 - Composé tétracyclique - Google Patents

Composé tétracyclique

Info

Publication number
MA33418B1
MA33418B1 MA34519A MA34519A MA33418B1 MA 33418 B1 MA33418 B1 MA 33418B1 MA 34519 A MA34519 A MA 34519A MA 34519 A MA34519 A MA 34519A MA 33418 B1 MA33418 B1 MA 33418B1
Authority
MA
Morocco
Prior art keywords
compound
cancer
agent
tetracyclic compound
formula
Prior art date
Application number
MA34519A
Other languages
Arabic (ar)
English (en)
Inventor
Kazutomo Kinoshita
Kohsuke Asoh
Noriyuki Furuichi
Toshiya Ito
Hatsuo Kawada
Nobuya Ishii
Hiroshi Sakamoto
Woosang Hong
Minjeong Park
Yoshiyuki Ono
Yasuharu Kato
Kenji Morikami
Takashi Emura
Nobuhiro Oikawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43308919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33418(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA33418B1 publication Critical patent/MA33418B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION A POUR OBJET UN AGENT THÉRAPEUTIQUE ET PRÉVENTIF EFFICACE CONTRE LES MALADIES ACCOMPAGNÉES D'UNE ANOMALIE DE L'ALK, TELLES QUE LES CANCERS, LES MÉTASTASES CANCÉREUSES, LA DÉPRESSION, OU LES DYSFONCTIONNEMENTS COGNITIFS, L'AGENT CONTENANT UN COMPOSÉ INHIBITEUR DE L'ALK. L'AGENT COMPREND UNE COMPOSITION MÉDICINALE CONTENANT UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE GÉNÉRALE (I) [CONCERNANT LES SYMBOLES DANS LA FORMULE, VOIR LES DÉFINITIONS DONNÉES DANS LA DESCRIPTION], UN SEL DU COMPOSÉ, OU UN SOLVATE DE L'UN OU DE L'AUTRE.
MA34519A 2009-06-10 2010-06-09 Composé tétracyclique MA33418B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009139691 2009-06-10
PCT/JP2010/059785 WO2010143664A1 (fr) 2009-06-10 2010-06-09 Composé tétracyclique

Publications (1)

Publication Number Publication Date
MA33418B1 true MA33418B1 (fr) 2012-07-03

Family

ID=43308919

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34519A MA33418B1 (fr) 2009-06-10 2010-06-09 Composé tétracyclique

Country Status (40)

Country Link
US (6) US9126931B2 (fr)
EP (4) EP2975024B1 (fr)
JP (2) JP4588121B1 (fr)
KR (1) KR101351120B1 (fr)
CN (1) CN102459172B (fr)
AR (1) AR077025A1 (fr)
AU (1) AU2010259588B2 (fr)
BR (1) BRPI1011649B1 (fr)
CA (1) CA2764653C (fr)
CL (1) CL2011002433A1 (fr)
CO (1) CO6430460A2 (fr)
CR (1) CR20110492A (fr)
CY (2) CY1117752T1 (fr)
DK (3) DK2975024T3 (fr)
EC (1) ECSP12011573A (fr)
ES (3) ES2668775T3 (fr)
FR (1) FR17C1019I2 (fr)
HK (1) HK1165794A1 (fr)
HR (3) HRP20160605T1 (fr)
HU (4) HUE039167T2 (fr)
IL (1) IL216817A (fr)
LT (3) LT3345903T (fr)
LU (1) LUC00022I2 (fr)
MA (1) MA33418B1 (fr)
MX (1) MX2011013306A (fr)
MY (1) MY159850A (fr)
NL (1) NL300876I2 (fr)
NO (2) NO2975024T3 (fr)
NZ (1) NZ597477A (fr)
PE (1) PE20121065A1 (fr)
PL (3) PL3345903T3 (fr)
PT (3) PT2975024T (fr)
RS (1) RS58855B1 (fr)
RU (2) RU2585622C3 (fr)
SG (1) SG175707A1 (fr)
SI (3) SI2975024T1 (fr)
TW (2) TWI624457B (fr)
UA (1) UA107796C2 (fr)
WO (1) WO2010143664A1 (fr)
ZA (1) ZA201106938B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2975024T (pt) * 2009-06-10 2018-05-14 Chugai Pharmaceutical Co Ltd Compostos tetracíclicos
EP3698788A1 (fr) * 2010-08-20 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Composition comprenant un composé tétracyclique
JP5006987B2 (ja) * 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
EP3815685A3 (fr) * 2011-10-31 2021-10-13 The Methodist Hospital Research Institute Composé comprenant un fragment de ciblage/recherche de mao pour le traitement de gliomes humains
CN106166155B (zh) * 2012-03-06 2019-01-18 赛福伦公司 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物
HUE040055T2 (hu) 2012-09-25 2019-02-28 Chugai Pharmaceutical Co Ltd RET inhibitor
JP2016503798A (ja) 2012-12-20 2016-02-08 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化ａｌｋ阻害剤
WO2014121654A1 (fr) * 2013-02-05 2014-08-14 山东轩竹医药科技有限公司 Inhibiteur de tétrazocyclokinase
JP6495238B2 (ja) * 2013-04-02 2019-04-03 トピバート ファーマ リミテッド キナーゼ阻害剤として有用な尿素誘導体
CN104109168B (zh) * 2013-04-20 2017-02-15 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104130241A (zh) * 2013-05-05 2014-11-05 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104177332A (zh) * 2013-05-20 2014-12-03 中国科学院上海药物研究所 酰胺基取代的吲哚并萘酮衍生物及其医药用途
CN104177342B (zh) * 2013-05-21 2018-01-05 中国科学院上海药物研究所 杂环基取代的吲哚并萘酮衍生物及其医药用途
CN105579459B (zh) * 2013-06-01 2018-03-13 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
JP2016522247A (ja) 2013-06-18 2016-07-28 ノバルティス アーゲー 組合せ医薬
CN104804016B (zh) * 2014-01-23 2017-06-20 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
WO2015163448A1 (fr) 2014-04-25 2015-10-29 中外製薬株式会社 Préparation contenant un composé tétracyclique à haute dose
WO2015163447A1 (fr) * 2014-04-25 2015-10-29 中外製薬株式会社 Nouveau cristal de composé tétracyclique
BR112016024421A2 (pt) * 2014-06-18 2017-08-15 Chugai Pharmaceutical Co Ltd composição farmacêutica, cápsula e uso da composição farmacêutica
TWI765410B (zh) * 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途
EP3202765B1 (fr) 2014-09-29 2020-03-25 Hainan Xuanzhu Pharma Co., Ltd. Inhibiteur de la kinase du lymphome anaplasique polycyclique
CN105566307B (zh) * 2014-10-11 2019-04-23 中国科学院上海药物研究所 一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途
CN104402862B (zh) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
US11077093B2 (en) 2015-01-16 2021-08-03 Chugai Seiyaku Kabushiki Kaisha Combination drug
US9573932B2 (en) * 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
US10358415B2 (en) * 2015-03-11 2019-07-23 International Flavors & Fragrances Inc. Processes for the preparation of unsaturated malonates
WO2016169504A1 (fr) 2015-04-24 2016-10-27 广州再极医药科技有限公司 Dérivé pyrimidylamino à cycle condensé, son procédé de préparation, et intermédiaire, composition pharmaceutique et applications associées
US10508082B2 (en) 2015-09-23 2019-12-17 Dana-Farber Cancer Institute, Inc. Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK
CN105777710B (zh) * 2016-04-05 2018-09-04 湖南欧亚药业有限公司 一种艾乐替尼的合成方法
CN106946650B (zh) * 2017-03-01 2021-06-08 南京远淑医药科技有限公司 一种盐酸阿雷替尼中间体的合成方法
CN106928184B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033125B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928125A (zh) * 2017-04-21 2017-07-07 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼中间体的制备方法
CN106928185B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107129488A (zh) * 2017-04-21 2017-09-05 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
CN106892860B (zh) * 2017-04-21 2019-08-02 湖南博奥德药业有限公司 一种艾乐替尼中间体的制备方法
CN107033124B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106995433A (zh) * 2017-04-21 2017-08-01 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
JP7160487B2 (ja) 2017-05-04 2022-10-25 ビーエーエスエフ ソシエタス・ヨーロピア 植物病原菌を駆除するための置換５－（ハロアルキル）－５－ヒドロキシ－イソオキサゾール
EP3649116A1 (fr) 2017-07-05 2020-05-13 Fresenius Kabi Oncology Limited Procédé de préparation d'alectinib ou d'un sel pharmaceutiquement acceptable de celui-ci
JP7054134B2 (ja) * 2017-12-07 2022-04-13 国立大学法人京都大学 ベンゾ［ｂ］カルバゾール化合物及びそれを用いたイメージング
WO2019114770A1 (fr) * 2017-12-13 2019-06-20 上海科技大学 Agent de dégradation de protéine alk et son application antitumorale
CN108178743A (zh) * 2018-02-08 2018-06-19 安庆奇创药业有限公司 一种艾乐替尼关键中间体的制备方法
CN110357889B (zh) * 2018-04-09 2022-03-15 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
WO2019211868A1 (fr) * 2018-04-30 2019-11-07 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation de chlorhydrate de 9-éthyl-6,6-diméthyl-8-[4-(morpholin-4-yl) pipéridin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile
MX2020014262A (es) 2018-06-29 2021-03-25 Chugai Pharmaceutical Co Ltd Composicion farmaceutica que comprende un agente basico poco soluble.
TWI825163B (zh) * 2018-09-04 2023-12-11 日商中外製藥股份有限公司 四環性化合物的製造方法
AU2019348006A1 (en) * 2018-09-27 2021-02-18 Dana-Farber Cancer Institute, Inc. Degraders that target Alk and therapeutic uses thereof
CN109438218B (zh) * 2018-10-23 2021-04-09 成都艾必克医药科技有限公司 一种盐酸艾乐替尼中间体2-(4-乙基-3-碘苯基)-2-甲基丙酸的合成方法
CN109384664B (zh) * 2018-11-20 2021-04-13 成都正善达生物医药科技有限公司 一种艾乐替尼中间体的制备方法
EP3556754A1 (fr) 2018-12-07 2019-10-23 Fresenius Kabi iPSUM S.r.l. Procédé de préparation d'alectinib
WO2020130125A1 (fr) 2018-12-21 2020-06-25 第一三共株式会社 Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase
CN111349012B (zh) * 2018-12-21 2023-01-10 上海复星星泰医药科技有限公司 一种卤代芳烃类化合物的制备方法及其中间体
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
CN110590739A (zh) * 2019-09-20 2019-12-20 中国药科大学 一种艾乐替尼的制备方法
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN116806152A (zh) 2021-01-29 2023-09-26 中外制药株式会社 儿童癌症治疗用药物组合物
EP4320153A1 (fr) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de traitement d'un lymphome anaplasique à grandes cellules
CN115340523B (zh) * 2021-05-12 2023-12-15 盛世泰科生物医药技术(苏州)股份有限公司 一种具有alk抑制活性的化合物及其制备方法和用途
CN118159274A (zh) 2021-10-28 2024-06-07 中外制药株式会社 糖浆剂
WO2023161233A1 (fr) 2022-02-22 2023-08-31 Synthon B.V. Formes solides d'alectinib et de sels d'alectinib
CN115677659B (zh) * 2022-10-11 2024-03-22 枣庄市润安制药新材料有限公司 一种阿雷替尼的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
DK0695755T3 (da) * 1994-08-04 1999-06-28 Hoffmann La Roche Pyrrolocarbazoler
JPH08291285A (ja) * 1995-04-21 1996-11-05 Fuji Photo Film Co Ltd 感光性組成物及びそれを用いた要素
EA001450B1 (ru) * 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
US6632822B1 (en) * 1999-05-14 2003-10-14 The Australian National University Compounds and therapeutic methods
WO2005009398A2 (fr) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Derives de benzamide tetracyclique et leurs procedes d'utilisation
ES2263862T3 (es) * 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2532800C (fr) 2003-07-23 2013-06-18 Exelixis, Inc. Modulateurs de la proteine alk (anaplastic lymphoma kinase) et leurs methodes d'utilisation
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
ES2308272T3 (es) 2003-11-21 2008-12-01 Novartis Ag Derivados de 1h-imidazoquinolina como inhibidores de la proteina quinasa.
WO2005056529A1 (fr) 2003-12-12 2005-06-23 Merck Frosst Canada Ltd. Inhibiteurs des proteases a cysteine du type cathepsine
JP4927704B2 (ja) 2004-03-19 2012-05-09 シュペーデル・エクスペリメンタ・アーゲー 有機化合物
CA2559866A1 (fr) * 2004-03-31 2005-10-20 Exelixis, Inc. Modulateurs de kinases de lymphomes anaplasiques (alk) et methodes d'utilisation
ES2341351T3 (es) 2004-08-26 2010-06-18 Pfizer, Inc. Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina cinasas.
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
RU2008122547A (ru) * 2005-11-07 2009-12-20 Айрм Ллк (Bm) Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) * 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
EP2142551B1 (fr) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Composés HÉTÉROCYCLIQUEs CONDENSÉS comme INHIBITEURS DE la 11-béta-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE I
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
BRPI0814628B1 (pt) 2007-07-20 2022-04-05 Nerviano Medical Sciences S.R.L. Derivados ativos de indazol substituídos como inibidores da quinase
JP5583592B2 (ja) * 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
CA2759581A1 (fr) 2009-05-07 2010-11-11 Astrazeneca Ab Composes 1-cyanoethylheterocyclylcarboxamide substitues 750
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
PT2975024T (pt) * 2009-06-10 2018-05-14 Chugai Pharmaceutical Co Ltd Compostos tetracíclicos
EP3698788A1 (fr) * 2010-08-20 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Composition comprenant un composé tétracyclique
HUE040055T2 (hu) * 2012-09-25 2019-02-28 Chugai Pharmaceutical Co Ltd RET inhibitor
WO2015163448A1 (fr) * 2014-04-25 2015-10-29 中外製薬株式会社 Préparation contenant un composé tétracyclique à haute dose
WO2015163447A1 (fr) * 2014-04-25 2015-10-29 中外製薬株式会社 Nouveau cristal de composé tétracyclique
BR112016024421A2 (pt) * 2014-06-18 2017-08-15 Chugai Pharmaceutical Co Ltd composição farmacêutica, cápsula e uso da composição farmacêutica
TWI765410B (zh) * 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途

Also Published As

Publication number Publication date
NO2017026I1 (no) 2017-06-12
ZA201106938B (en) 2012-12-27
EP2441753A1 (fr) 2012-04-18
RU2725140C2 (ru) 2020-06-30
JP4588121B1 (ja) 2010-11-24
US20230142119A1 (en) 2023-05-11
JP2011016830A (ja) 2011-01-27
FR17C1019I1 (fr) 2017-07-21
AR077025A1 (es) 2011-07-27
KR101351120B1 (ko) 2014-01-15
CN102459172A (zh) 2012-05-16
CL2011002433A1 (es) 2012-02-17
ES2668775T3 (es) 2018-05-22
US20160340308A1 (en) 2016-11-24
ECSP12011573A (es) 2012-02-29
US9440922B2 (en) 2016-09-13
EP2975024B1 (fr) 2018-03-28
LUC00022I2 (fr) 2017-09-08
WO2010143664A1 (fr) 2010-12-16
HUE028278T2 (en) 2016-12-28
HUE039167T2 (hu) 2018-12-28
HRP20160605T1 (hr) 2016-07-01
SI3345903T1 (sl) 2020-02-28
PE20121065A1 (es) 2012-08-28
TWI531367B (zh) 2016-05-01
ES2759510T3 (es) 2020-05-11
CY1117752T1 (el) 2017-05-17
EP3345903A1 (fr) 2018-07-11
MY159850A (en) 2017-02-15
LT2975024T (lt) 2018-06-11
CY2017026I2 (el) 2017-11-14
KR20120034677A (ko) 2012-04-12
LTPA2017017I1 (lt) 2017-06-26
TW201613858A (en) 2016-04-16
CA2764653C (fr) 2018-01-02
RS20110548A1 (en) 2012-08-31
AU2010259588A1 (en) 2011-10-06
CA2764653A1 (fr) 2010-12-16
RS58855B1 (sr) 2019-07-31
HUE046402T2 (hu) 2020-03-30
HRP20192022T1 (hr) 2020-02-07
SI2975024T1 (en) 2018-05-31
RU2585622C3 (ru) 2021-08-02
PT2975024T (pt) 2018-05-14
HRP20180615T1 (hr) 2018-06-01
EP3613729A1 (fr) 2020-02-26
HUS1700026I1 (hu) 2017-07-28
ES2575084T3 (es) 2016-06-24
US20120083488A1 (en) 2012-04-05
TWI624457B (zh) 2018-05-21
NO2975024T3 (fr) 2018-08-25
RU2015156881A (ru) 2019-01-18
AU2010259588B2 (en) 2015-05-28
PT2441753E (pt) 2016-06-16
LTC2441753I2 (lt) 2019-02-25
RU2011154150A (ru) 2013-07-20
DK3345903T3 (da) 2019-11-11
RU2015156881A3 (fr) 2019-08-08
PT3345903T (pt) 2019-12-09
EP2441753B1 (fr) 2016-03-30
NL300876I2 (nl) 2017-07-11
IL216817A (en) 2016-05-31
TW201103537A (en) 2011-02-01
SI2441753T1 (sl) 2016-07-29
EP2441753A4 (fr) 2014-08-27
DK2975024T3 (en) 2018-04-23
UA107796C2 (en) 2015-02-25
LUC00022I1 (fr) 2017-06-15
IL216817A0 (en) 2012-02-29
EP2975024A1 (fr) 2016-01-20
US20220306578A1 (en) 2022-09-29
MX2011013306A (es) 2012-01-12
PL3345903T3 (pl) 2020-02-28
CR20110492A (es) 2012-03-08
LT3345903T (lt) 2019-12-10
CN102459172B (zh) 2015-06-24
US20150150845A1 (en) 2015-06-04
NO2017026I2 (no) 2017-06-12
NL300876I1 (nl) 2017-06-14
PL2975024T3 (pl) 2018-09-28
JPWO2010143664A1 (ja) 2012-11-29
HK1165794A1 (en) 2012-10-12
BRPI1011649B1 (pt) 2021-11-30
BRPI1011649A2 (pt) 2021-04-20
SG175707A1 (en) 2011-12-29
RU2585622C2 (ru) 2016-05-27
CO6430460A2 (es) 2012-04-30
EP3345903B1 (fr) 2019-10-09
FR17C1019I2 (fr) 2018-04-27
US9126931B2 (en) 2015-09-08
NZ597477A (en) 2014-03-28
CY2017026I1 (el) 2017-11-14
DK2441753T3 (en) 2016-05-30
PL2441753T3 (pl) 2016-09-30
JP5628603B2 (ja) 2014-11-19
US20200017442A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
MA33418B1 (fr) Composé tétracyclique
EA200970156A1 (ru) Пиридизиноновые производные
PH12016501048A1 (en) Piperidine derivatives as mdm2 inhibitors for the treatment of cancer
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
MY153915A (en) Organic compounds
SG179418A1 (en) Inhibitors of the hedgehog pathway
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
WO2008036652A3 (fr) Amidines servant de modulateurs d'indoléamine 2,3-dioxygénase
MX2009006473A (es) Inhibidores de receptor vainilloide de bencimidazol.
SG158091A1 (en) Imidazoazepinone compounds
MX2011008195A (es) Derivados de indol como agentes anticancer.
EA201000703A1 (ru) Производные пиразола в качестве ингибиторов 5-lo
RS53002B (en) ANTI-CANCER UNIT AND PHARMACEUTICAL COPMOSITION CONTAINING IT
IL191670A0 (en) Compounds for the inhibition of apoptosis
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TN2010000583A1 (en) Organic compounds